TapRoot Partners with Psychiatric Provider Group Peace of Mind Consultants to Use Ella®

TapRoot Interventions & Solutions, Inc (TapRoot) is partnering with psychiatric and behavioral health provider group Peace of Mind Consultants (POMC) in Arizona to provide Ella® to their patients and business partners. Ella is a digital careplan platform that provides  interventions to prevent, decrease, and de-escalate dementia-related and mental illness-related behavioral symptoms known to occur in  Long Term Care communities. POMC will use Ella to garner key insights from caregiver feedback in order to tailor patient-specific treatment plans and determine appropriate use of medications. The value of the partnership is a provider service model coupled with a caregiver platform to assess, evaluate, and provide outcome measures to improve overall resident care.Continue reading

C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies

TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading

U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

  • This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
  • With the approval of HEMGENIX, CSL now offers an even more comprehensive portfolio of treatments for people living with hemophilia B, ushering in a new era of treatment options 


Continue reading

Ultrasound activated microbubbles enhance the activity of standard of care therapeutics in pancreatic cancer

PHOENIX, Arizona and OSLO, Norway — November 21, 2022 — Scientists at the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, and EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a Norwegian clinical stage precision health company, today report that the ultrasound based Acoustic Cluster Therapy (ACT®) significantly enhanced the antitumor efficacy of standard care therapies in a preclinical model for pancreatic cancer.Continue reading